![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: OLAH |
Gene summary for OLAH |
![]() |
Gene information | Species | Human | Gene symbol | OLAH | Gene ID | 55301 |
Gene name | oleoyl-ACP hydrolase | |
Gene Alias | AURA1 | |
Cytomap | 10p13 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9NV23 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55301 | OLAH | HCC1 | Human | Liver | HCC | 1.22e-06 | 8.09e-01 | 0.5336 |
55301 | OLAH | HCC2 | Human | Liver | HCC | 8.14e-17 | 1.51e+00 | 0.5341 |
55301 | OLAH | HCC5 | Human | Liver | HCC | 2.29e-15 | 1.09e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
GO:000663321 | Liver | HCC | fatty acid biosynthetic process | 96/7958 | 163/18723 | 1.71e-05 | 1.85e-04 | 96 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OLAH | SNV | Missense_Mutation | novel | c.6N>T | p.Glu2Asp | p.E2D | Q9NV23 | protein_coding | tolerated_low_confidence(0.42) | benign(0.018) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
OLAH | SNV | Missense_Mutation | rs140879602 | c.205C>T | p.Arg69Trp | p.R69W | Q9NV23 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-A2-A4RY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
OLAH | SNV | Missense_Mutation | rs145059634 | c.578N>A | p.Arg193His | p.R193H | Q9NV23 | protein_coding | tolerated(0.34) | benign(0.01) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
OLAH | SNV | Missense_Mutation | c.889N>T | p.Ala297Ser | p.A297S | Q9NV23 | protein_coding | tolerated(1) | benign(0.019) | TCGA-D8-A1JB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
OLAH | SNV | Missense_Mutation | novel | c.746N>G | p.Ser249Cys | p.S249C | Q9NV23 | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
OLAH | SNV | Missense_Mutation | novel | c.173N>T | p.Ser58Phe | p.S58F | Q9NV23 | protein_coding | tolerated_low_confidence(0.68) | benign(0) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
OLAH | SNV | Missense_Mutation | c.905N>A | p.Ile302Asn | p.I302N | Q9NV23 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AA-3488-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
OLAH | SNV | Missense_Mutation | rs145059634 | c.578N>A | p.Arg193His | p.R193H | Q9NV23 | protein_coding | tolerated(0.34) | benign(0.01) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
OLAH | SNV | Missense_Mutation | novel | c.912N>A | p.Asn304Lys | p.N304K | Q9NV23 | protein_coding | tolerated(0.21) | benign(0.203) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OLAH | SNV | Missense_Mutation | novel | c.935T>G | p.Val312Gly | p.V312G | Q9NV23 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |